Swiss pharma manufacturing to expand with CHF 25.5 million investment

CARBOGEN AMCIS, a Swiss pharmaceutical process development and API manufacturing company, has announced a major co-investment exceeding CHF 25 million to expand its production capabilities at its Aarau and Neuland sites in Switzerland. This strategic move supports increased demand for a drug linker used in a commercial antibody-drug conjugate (ADC).

The investment includes significant upgrades to both sites. At Aarau, new 850-litre reactors and 0.4 m² agitated filter dryers will be installed, with completion targeted for the first quarter of 2027. Meanwhile, the Neuland site will see similar equipment additions, expected to be operational by the third quarter of 2027.

This expansion builds on a previous joint funding effort from 2021, reinforcing the long-term collaboration between CARBOGEN AMCIS and its Japanese customer. The partnership highlights a shared commitment to scaling up production to meet the evolving needs of complex, high-value pharmaceutical compounds.

Stephan Fritschi, CEO of CARBOGEN AMCIS, emphasised the company’s ability to grow alongside its customers: “This investment allows us to respond to rising demand for advanced therapies such as ADC drug linkers while maintaining our technical excellence and operational standards.”

Known for its expertise in handling highly potent compounds, CARBOGEN AMCIS provides comprehensive services from process development through commercial manufacturing. The new equipment and infrastructure upgrades will enhance the company’s capacity to deliver high-quality, cGMP-compliant manufacturing solutions in line with global regulatory requirements.

Carl Baker, Vice President of the Business Unit Drug Substance, added: “Upgrading our Aarau and Neuland facilities ensures we can meet increasing production volumes without compromising containment controls and operational quality.”
With additional sites in France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint, providing integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

More information online